. 2022 Apr 28;17(4):e0266889. doi: 10.1371/journal.pone.0266889

Table 3. False positive rate.

Solid tumor Mutations		Number of Mutations Detected			False Positive
Solid tumor Mutations		1%	0.50%	0.125%	0%
A	50ng	37(100%)	36(97%)	26(70%)	0(0%)
A	10ng	37(100%)	36(97%)	23(62%)	1(3%)
B	50ng	38(100%)	38(100%)	38(100%)	0(0%)
B	10ng	38(100%)	38(100%)	33(87%)	0(0%)
C	50ng	38(100%)	37(97%)	34(89%)	1(3%)
C	10ng	38(100%)	37(97%)	23(61%)	0(0%)
^* D	50ng	5(100%)	5(100%)	4(80%)	1(20%)
^* D	10ng	5(100%)	5(100%)	2(40%)	0(0%)
E	50ng	37(100%)	36(97%)	36(97%)	4(11%)
E	10ng	37(100%)	35(95%)	19(51%)	1(3%)
Myeloid Mutations		Number of Mutations Detected			False Positive
Myeloid Mutations		1%	0.50%	0.13%	0%
A	50ng	15(94%)	15(94%)	4(25%)	0(0%)
A	10ng	15(94%)	13(81%)	4(25%)	0(0%)
B	50ng	17(100%)	17(100%)	17(100%)	0(0%)
B	10ng	17(100%)	17(100%)	11(65%)	0(0%)
C	50ng	16(94%)	15(88%)	8(47%)	0(0%)
C	10ng	16(94%)	15(88%)	1(6%)	0(0%)
E	50ng	17(100%)	17(100%)	17(100%)	6(35%)
E	10ng	17(100%)	17(100%)	12(71%)	2(12%)

*5 reference mutations were covered by the assay